Skip to content

US · RMTI · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Rockwell Medical, Inc. (RMTI) intrinsic value and stock valuation

$5.82as of 2026-11-21 · Mkt cap 28.66M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Rockwell Medical, Inc. DCF and intrinsic value

InvestorsCraft values RMTI with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from RMTI’s statements →

Rockwell Medical, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Wixom, MI 48393 rockwellmed.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$69.3M+2.2% 5y CAGRd
20112025
Net income
-$-5.31M
20112025
Free cash flow
-$-1.2M
20112025
Total equity
$37M+1.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$69.3M$101.5M$83.6M$72.8M$61.9M
Operating income-$-4.69M$610K-$-6.67M-$-16.78M-$-30.34M
Net income-$-5.31M-$-480K-$-8.44M-$-18.68M-$-32.67M
EPSd-$-1.47M-$-154.34K-$-3.62M-$-18.87M-$-38.44M
Operating cash flow-$-660K$4.2M-$-9.41M-$-16.93M-$-33.53M
Capital expenditure-$-540K-$-1.01M-$-280K-$-280K-$-520K
Free cash flow-$-1.2M$3.19M-$-9.7M-$-17.21M-$-34.06M
Total assets$57.2M$59.2M$52.2M$46.6M$48.6M
Total debt$12.5M$13.5M$13.4M$16.4M$28.9M
Net debt$1.76M-$-2.13M$4.46M$6.26M$15.6M
Total equity$37M$32.6M$21.3M$14.1M$2.54M
Cash and short-term investments$25M$21.6M$10.9M$21.5M$22.4M
Income statement
20252024202320222021
Revenue$69.3M$101.5M$83.6M$72.8M$61.9M
Cost of revenue$57.6M$84M$74.9M$68.7M$64.4M
Gross profit$11.7M$17.5M$8.7M$4.08M-$-2.42M
Research and development expenses$0.00$20K$1.11M$3.12M$6.83M
Selling, general and administrative expenses$16.4B$16.9M$14.3M$17.7M$21.1M
Other expenses-$-16.37B$0.00$0.00$0.00$0.00
Operating expenses$16.4M$16.9M$15.4M$20.9M$27.9M
Cost and expenses$74M$100.9M$90.3M$89.6M$92.3M
Interest income$230K$90K$210K$30K$20K
Interest expense$1.12M$1.25M$2.3M$1.94M$2.36M
Depreciation and amortization$2.19M$2.18M$1.44M$580K$2.52M
Ebitda-$-2M$2.95M-$-4.69M-$-16.17M-$-27.8M
Operating income-$-4.69M$610K-$-6.67M-$-16.78M-$-30.34M
Total other income/expenses, net-$-620K-$-1.09M-$-1.77M-$-1.9M-$-2.34M
Income before tax-$-5.31M-$-480K-$-8.44M-$-18.68M-$-32.67M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-5.31M-$-480K-$-8.44M-$-18.68M-$-32.67M
Weighted average shares outstanding$3.6M$3.11M$2.33M$990K$850K
Weighted average diluted shares outstanding$3.6M$3.11M$2.33M$990K$850K
Balance sheet
20252024202320222021
Cash and short-term investments$25M$21.6M$10.9M$21.5M$22.4M
Net receivables$8.14M$8.29M$10.9M$6.26M$5.91M
Inventory$3.42M$5.78M$5.87M$5.81M$4.08M
Total current assets$38.2M$37M$28.8M$35.3M$35.3M
Property, plant and equipment, net$7.85M$10.3M$11M$8.61M$10.2M
Goodwill and intangible assets$10.6M$11.1M$11.7M$920K$920K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$19M$22.2M$23.4M$11.3M$13.3M
Total assets$57.2M$59.2M$52.2M$46.6M$48.6M
Accounts payable$2M$2.87M$4.52M$4.05M$3.74M
Short-term debt$1.89M$2.43M$2.18M$4.14M$9.82M
Deferred revenue$360K$140K$290K$1.8M$2.31M
Total current liabilities$9.58M$14.1M$16.6M$17.7M$21M
Long-term debt$10.6M$11.1M$11.3M$12.2M$19.1M
Deferred revenue, non-current$0.00$430K$470K$2.6M$5.99M
Total non-current liabilities$10.6M$12.5M$14.2M$14.8M$25.1M
Capital lease obligations$3.38M$4.79M$4.9M$6.67M$7.89M
Total liabilities$20.2M$26.6M$30.9M$32.5M$46M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-402.99M-$-397.68M-$-397.2M-$-388.76M-$-370.08M
Accumulated other comprehensive income (loss)$130K$50K-$0.00$160K$50K
Total equity$37M$32.6M$21.3M$14.1M$2.54M
Total investments$14.3M$5.94M$1.95M$11.4M$9.16M
Total debt$12.5M$13.5M$13.4M$16.4M$28.9M
Net debt$1.76M-$-2.13M$4.46M$6.26M$15.6M
Cash flow statement
20252024202320222021
Net income-$-5.31M-$-480K-$-8.44M-$-18.68M-$-32.67M
Depreciation and amortization$2.19M$2.18M$1.44M$580K$2.52M
Stock-based compensation$1.82M$1.29M$930K$320K$940K
Change in working capital-$-1.61M-$-1.53M-$-7.24M-$-2.13M-$-4.84M
Accounts receivable-$-100K$2.61M-$-4.64M-$-350K-$-1.74M
Inventory$2.78M-$-330K$1.18M-$-2.1M-$-660K
Accounts payable-$-870K-$-1.65M$460K$310K-$-420K
Net cash provided by operating activities-$-660K$4.2M-$-9.41M-$-16.93M-$-33.53M
Investments in property, plant and equipment-$-540K-$-1.01M-$-280K-$-280K-$-520K
Acquisitions, net$0.00$0.00-$-12.36M$0.00-$-830K
Net cash used for investing activities-$-8.54M-$-4.87M-$-3.04M-$-2.4M$310K
Common stock issued$7.82M$10.2M$14.9M$15M$110K
Common stock repurchased$0.00$0.00$0.00$0.00-$-10K
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$4.25M$7.35M$11.3M$16.2M-$-2.18M
Net change in cash-$-4.95M$6.68M-$-1.12M-$-3.18M-$-35.4M
Cash at end of period$10.7M$15.7M$8.98M$10.1M$13.3M
Operating cash flow-$-660K$4.2M-$-9.41M-$-16.93M-$-33.53M
Capital expenditure-$-540K-$-1.01M-$-280K-$-280K-$-520K
Free cash flow-$-1.2M$3.19M-$-9.7M-$-17.21M-$-34.06M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Rockwell Medical, Inc.

        Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain healthy hemoglobin levels in dialysis patients, notably without increasing existing iron stores. Beyond iron management, Rockwell Medical manufactures, sells, and distributes a comprehensive range of hemodialysis concentrates. These include various acid concentrates such as CitraPure (citric), Dri-Sate (dry), and RenalPure (liquid), alongside a dry acid concentrate mixer, and powder bicarbonate concentrates like RenalPure and SteriLyte. These crucial products are vital for sustaining life in dialysis patients by facilitating the removal of toxins and the replacement of essential nutrients in their bloodstream. The company further supplies ancillary items critical for hemodialysis procedures. This extensive catalog comprises blood tubing, fistula needles, dialyzers, pharmaceuticals, specialized component kits, dressings, cleaning agents, filtration salts, and other necessary provisions utilized by hemodialysis providers. Looking to the future, Rockwell Medical is actively developing additional therapeutic candidates. These include treatments for hospitalized individuals suffering from acute heart failure, as well as solutions for home infusion therapy, enabling patients to receive intravenous medications in a home setting. The company primarily serves medium and small-sized dialysis chains, as well as independent dialysis centers. Established in 1996, Rockwell Medical, Inc. maintains its corporate headquarters in Wixom, Michigan.

        CEO
        Mark Strobeck
        Employees
        157
        Beta
        1.61

        Explore

        Frequently asked questions

        What is the intrinsic value of Rockwell Medical, Inc. (RMTI)?

        InvestorsCraft does not currently publish an intrinsic value for RMTI. How the IC value is calculated.

        Is RMTI undervalued?

        InvestorsCraft does not publish an undervaluation signal for RMTI at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.